drugset / Trial / NCT05749133
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
NaSingle-groupOpen-labelTreatment
Summary
It is a single-center, open-labeled, single-arm, non-randomized investigatorinitiated trial evaluating the efficacy and safety of anti-GPRC5D CAR-T cells therapy for relapsed and refractory(r/r) multiple myeloma(MM) after three or more lines of treatments.
Timeline
- Start
- 2023-04-10
- Primary completion
- 2025-03
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-GPRC5D CAR-T | Cell therapy | 3 cells/kg | Intravenous |
| Subject | Anti-GPRC5D CAR-T | Cell therapy | 6 cells/kg | Intravenous |